Loading...
•
Jun 30, 2020
PDS Biotechnology Q2 2020 Earnings Report
PDS Biotechnology reported financial results for the second quarter of 2020 and provided a business update.
Key Takeaways
PDS Biotechnology reported a net loss of $2.9 million, or $0.19 per share, for the second quarter of 2020. Research and development expenses totaled $1.4 million, while general and administrative expenses were $1.5 million. The company's cash balance as of June 30, 2020, was $16.9 million.
Announced publication of PDS0101 triple combination preclinical study by the National Cancer Institute.
Initiated Phase 2 clinical trial of PDS0101 triple combination, led by the National Cancer Institute, for the treatment of advanced human papillomavirus (HPV)-associated cancers.
Launched novel PDS Biotech-owned vaccine development programs for COVID-19, PDS0203, and universal influenza, PDS0202.
Expanded existing Cooperative Research and Development Agreement with the National Cancer Institute to include preclinical and clinical development of PDS0103 in MUC-1 expressing- cancers including breast, colon, lung and ovarian cancers.
PDS Biotechnology
PDS Biotechnology
Forward Guidance
PDS Biotech is positioned to progress programs through initial human clinical data generation over the next 12-18 months.